Do antidepressants, and specifically SSRIs, do more harm than good? The acrimonious debate between colleagues in the wake of yet another meta-analysis, this time by Jakobsen et al. (1), suggests we don't know (2, 3) . Or rather, we don't know how to interpret the facts that randomised clinical trials provide for us to reach a conclusion that everyone can and perhaps should accept.
groups. Such effects would not be detected in short-term trials but might emerge from cohort studies in much larger populations.
Much the most common harms are the direct adverse reactionsthe 'side effects'of taking a drug. These are recorded either by spontaneous report or systematic questioning. Absolute numbers are always higher when elicited by the latter method. In the case of the SSRIs, the most common are abdominal queasiness (at worse nausea and vomiting), and changes in sexual function. These symptoms are relatively common at some level of severity. Clinical experience suggests that these adverse reactions are sometimes but not often an important reason why patients do not take their medicines. However, they are not irreversible harms. Indeed, they are trivial compared with the adverse effects that some drugs can directly cause. Moreover, they are normally easily reversible.
Whether benefits outweigh harms is not answered by counting large numbers of subjective complaints. The best approach is probably to look at patient behaviour. Drop out rate is the key metric recommended in the most recent meta-analysis by Cipriani et al. (10) . This is the net effect of benefit, which will motivate patients to take a tablet, and cost (the trouble of taking an ineffective treatment and /or its adverse effects). The trials themselves show that acceptability of all SSRI antidepressants is positive (Cipriani et al., fig 3b) (10) . For no SSRI is the drop out rate statistically higher than placebo, which is what the literal interpretation of doing more harm than good would require.
In conclusion, in our view, Jacobsen et al. down play the benefits of SSRIs and they inflate the harms. Their argument about efficacy can be answered to show that the clinical trials support an average effect that is fully comparable with drugs used for physical disorders. Moreover, subgroups and individuals probably benefit substantially more. How many people in trials do not actually take the pills they are prescribed, for example? The challenge is to personalise treatment choice and amplify treatment effects with psychotherapy or neurostimulation. Jacobsen et al.'s emphasis on serious harms is probably spurious, when based on the trial data. The excess of more trivial harmsadverse reactionsis certainly real but it does not lead to high rates of drug discontinuation. Their management is part of clinical practice.
No one suggests the efficacy of SSRIs is better than moderate. The glass is half full but it is not empty, the challenge is to move on and fill it further.
